You just read:

ThromboGenics and BioInvent Have Dosed the First Patient in Phase IIb Trial of TB-402 (Anti-Factor VIII) for Venous Thromboembolism (VTE) Prophylaxis

News provided by

ThromboGenics NV

Apr 27, 2011, 01:30 ET